These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8638994)

  • 1. Duration of the survival benefit of zidovudine therapy in HIV infection.
    Moore RD; Keruly JC; Chaisson RE
    Arch Intern Med; 1996 May; 156(10):1073-7. PubMed ID: 8638994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects on survival of early treatment of human immunodeficiency virus infection.
    Graham NM; Zeger SL; Park LP; Vermund SH; Detels R; Rinaldo CR; Phair JP
    N Engl J Med; 1992 Apr; 326(16):1037-42. PubMed ID: 1347907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early participation in an HIV cohort study slows disease progression and improves survival. The Swiss HIV Cohort Study.
    Battegay M; Wirz M; Steuerwald MH; Egger M
    J Intern Med; 1998 Dec; 244(6):479-87. PubMed ID: 9893101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease.
    Erbelding EJ; Chaisson RE; Gallant JE; Moore RD
    Antivir Ther; 1997 Apr; 2(2):71-7. PubMed ID: 11322278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
    Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
    Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
    Justice AC; Stein DS; Fusco GP; Sherrill BH; Fusco JS; Danehower SC; Becker SL; Hansen NI; Graham NM;
    J Clin Epidemiol; 2004 Jan; 57(1):89-97. PubMed ID: 15019015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.
    Gallant JE; Moore RD; Richman DD; Keruly J; Chaisson RE
    Arch Intern Med; 1994 Mar; 154(5):566-72. PubMed ID: 8122950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Race, sex, drug use, and progression of human immunodeficiency virus disease.
    Chaisson RE; Keruly JC; Moore RD
    N Engl J Med; 1995 Sep; 333(12):751-6. PubMed ID: 7643881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients.
    Easterbrook PJ; Emami J; Gazzard B
    AIDS; 1993 Oct; 7(10):959-67. PubMed ID: 7903542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
    Hoffmann C; Chow KU; Wolf E; Faetkenheuer G; Stellbrink HJ; van Lunzen J; Jaeger H; Stoehr A; Plettenberg A; Wasmuth JC; Rockstroh J; Mosthaf F; Horst HA; Brodt HR
    Br J Haematol; 2004 May; 125(4):455-62. PubMed ID: 15142115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
    Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retention in care: a challenge to survival with HIV infection.
    Giordano TP; Gifford AL; White AC; Suarez-Almazor ME; Rabeneck L; Hartman C; Backus LI; Mole LA; Morgan RO
    Clin Infect Dis; 2007 Jun; 44(11):1493-9. PubMed ID: 17479948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
    Thiessard F; Morlat P; Marimoutou C; Labouyrie E; Ragnaud JM; Pellegrin JL; Dupon M; Dabis F
    Cancer; 2000 Apr; 88(7):1696-702. PubMed ID: 10738229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. The Italian register for HIV Infection in Children.
    AIDS; 1999 May; 13(8):927-33. PubMed ID: 10371173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.